Head-to-head Comparison Between Direct Oral Anticoagulants and Vitamin K Antagonists for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis

Article Cardiac & Cardiovascular Systems

Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension

Marc Humbert et al.

Summary: This study reports the outcomes of patients with chronic thromboembolic pulmonary hypertension receiving either a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant. The rates of adverse events and serious adverse events were similar between the two groups, but the non-vitamin K antagonist group had a higher rate of embolic and/or thrombotic events.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2022)

Add to Collection

Review Pharmacology & Pharmacy

Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombus: A Systematic Review and Meta-analysis

Cameron Burmeister et al.

Summary: DOACs appear to be more efficacious in achieving LVT resolution compared with VKAs, but there were no significant differences between the two groups in terms of other outcomes, further randomized controlled trials are needed to confirm the findings.

AMERICAN JOURNAL OF THERAPEUTICS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China

Ke-Xin Sun et al.

Summary: The study conducted a cost-effectiveness analysis of VTE treatment in China using a Markov model, indicating that RIV may be the most cost-effective option. Sensitivity analysis and probabilistic sensitivity analysis confirmed this conclusion, providing valuable guidance for clinical decision-making by healthcare professionals.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy